S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,691.01 +1.24%

S&P 500 7,457.69 -1.01% NASDAQ 25,520.24 -1.40% DOW 52,146.42 -0.77% R2K 2,962.22 -0.42% VIX 18.77 +12.19% US 10Y 4.54 -0.61% DXY 100.75 +0.02% GOLD 4,012.70 +0.68% CRUDE 82.49 +4.48% BITCOIN 64,691.01 +1.24%

Next Bullish Trade

Sign in

Account

Create free accountFree dashboard, no payment Sign inEmail yourself a login link CoursesYour library & catalog

NBIX

NBIX

+ Compare Open in Sniper

News · NBIX

Full news feed →

Tom Lee's Small-Cap Granny Shots ETF Reloads: First Solar, Zoom Among 10 New Buys

Benzinga · 38d ago

Nxera Pharma Operational Highlights and Consolidated Results for the First Quarter 2026

GlobeNewswire Inc. · 78d ago

Nxera Pharma’s Partner Neurocrine Biosciences Doses First Patient in Phase 2 Trial of NBI-1117570 for Adults with Schizophrenia

GlobeNewswire Inc. · 96d ago

Why Soleno Therapeutics Stock Rocketed Higher on Monday

The Motley Fool · 103d ago

Neurocrine Buys Soleno To Tap High-Growth Rare Disease Market

Benzinga · 103d ago

Biohaven Stock Down 70% but One Fund's New $6 Million Bet Signals Turnaround Potential

The Motley Fool · 117d ago

Analysts Stay Bullish As Neurocrine Shares Tumble On Disappointing Ingrezza Guidance

Benzinga · 156d ago

Clinical Miss For Neurocrine's Cerebral Palsy Drug, But Analysts See Limited Damage

Benzinga · 207d ago

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?

The Motley Fool · 226d ago

Neurocrine (NBIX) Q2 Revenue Jumps 17%

The Motley Fool · 351d ago

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

GlobeNewswire Inc. · 367d ago

Nxera Pharma to Receive US$15 Million from Neurocrine Biosciences Following Dosing of First Patient in Phase 3 Trial of NBI-1117568

GlobeNewswire Inc. · 410d ago

Nxera Pharma Notes Neurocrine Biosciences Presents New Positive Data from Phase 2 Study of NBI-1117568 in Adults with Schizophrenia at American Society of Clinical Psychopharmacology 2025

GlobeNewswire Inc. · 415d ago

Sodium Channel Blockers Clinical Trial Pipeline Accelerates as 20+ Pharma Companies Rigorously Developing Drugs for Market Entry | DelveInsight

GlobeNewswire Inc. · 465d ago

Acetylcholine Receptor Antagonists Clinical Trial Pipeline Appears Robust With 30+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight

GlobeNewswire Inc. · 499d ago

Why Neurocrine Biosciences Stock Sank Today

The Motley Fool · 522d ago

Neurocrine Biosciences Reports Mixed Q4

The Motley Fool · 526d ago

Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights

Benzinga · 536d ago

Rare Endocrinology and Metabolic Disorders Market Analysis: Emerging Trends and Future Outlook of Hypophosphatasia, Congenital Adrenal Hyperplasia, and Severe Hypertriglyceridemia | DelveInsight

GlobeNewswire Inc. · 555d ago

Neurocrine's Drug Gains FDA Nod As First Targeted Treatment For Certain Type Of Inherited Disorder, Analyst Highlights Blockbuster Potential

Benzinga · 579d ago

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

GlobeNewswire Inc. · 619d ago

Tardive Dyskinesia (TD) Market Research 2024: Epidemiology, Treatment Landscape, Unmet Needs, Emerging Therapies, and Value & Access

GlobeNewswire Inc. · 683d ago

Dollar General, Temu Parent PDD And Super Micro Computer Are Among Top 10 Large Cap Losers Last Week (Aug 25-Aug 31): Are The Others In Your Portfolio?

Benzinga · 684d ago

Why Neurocrine Biosciences Stock Was Tumbling This Week

The Motley Fool · 687d ago

Key Takeaways From Neurocrine Biosciences Analyst Ratings

Benzinga · 781d ago